Core Viewpoint - A class action lawsuit has been filed against Zenas BioPharma, alleging that the company made false and misleading statements in its registration statement related to its September 2024 initial public offering [1][3]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of Massachusetts on behalf of all individuals and entities who purchased Zenas BioPharma securities during the class period [1]. - Investors have until June 16, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations - The complaint alleges that Zenas BioPharma materially overstated the duration it could fund its operations using existing cash and expected net proceeds from the IPO [3]. - It is claimed that the public statements made by the defendants were materially false and misleading at all relevant times and were negligently prepared [3].
ZENAS BIOPHARMA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Zenas BioPharma, Inc. and Encourages Investors to Contact the Firm